High Serum Phosphorus Level Is Associated with Left Ventricular Diastolic Dysfunction in Peritoneal Dialysis Patients

Min Ye¹, Na Tian²,³, Yanqiu Liu¹, Wei Li¹, Hong Lin¹, Rui Fan¹, Cuiling Li¹, Donghong Liu¹*, Fengjuan Yao¹*

¹ Department of Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China,
² Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China,
³ Department of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, PR China

☯ These authors contributed equally to this work.
* yaofengjuan@hotmail.com (FJY); pyldhj@hotmail.com (DHL)

Abstract

Objectives

We initiated this study to explore the relationships of serum phosphorus level with left ventricular ultrasound features and diastolic function in peritoneal dialysis (PD) patients.

Methods

174 patients with end-stage renal disease (ESRD) receiving PD were enrolled in this retrospective observational study. Conventional echocardiography examination and tissue Doppler imaging (TDI) were performed in each patient. Clinical information and laboratory data were also collected. Analyses of echocardiographic features were performed according to phosphorus quartiles groups. And multivariate regression models were used to determine the association between serum phosphorus and left ventricular diastolic dysfunction (LVDD).

Results

With the increase of serum phosphorus levels, patients on PD showed an increased tissue Doppler-derived E/e’ ratio of lateral wall (P < 0.001), indicating a deterioration of left ventricular diastolic function. Steady growths of left atrium and left ventricular diameters as well as increase of left ventricular muscle mass were also observed across the increasing quartiles of phosphorus, while left ventricular ejection fraction remained normal. In a multivariate analysis, the regression coefficient for E/e’ ratio in the highest phosphorus quartile was almost threefold higher relative to those in the lowest quartile group. And compared with patients in the lowest phosphorus quartile (<1.34 mmol/L) those in the highest phosphorus quartile (>1.95 mmol/L) had a more than fivefold increased odds of E/e’ ratio >15.
Conclusions
Our study showed an early impairment of left ventricular diastolic function in peritoneal dialysis patients. High serum phosphorus level was independently associated with greater risk of LVDD in these patients. Whether serum phosphorus will be a useful target for prevention or improvement of LVDD remains to be proved by further studies.

Introduction
Cardiovascular disease (CVD) is the leading cause of death among patients with ESRD [1–2], accounting for more than 50% of overall mortality [3]. The cardiovascular mortality risk in patients with ESRD starting dialysis was estimated to be 15-fold higher compared with the age-, race-, and sex-matched general population [4]. Left ventricular diastolic dysfunction occurs frequently in chronic kidney disease (CKD) patients and even in patients with early stages of chronic kidney dysfunction [5]. And it has been proved as predictive of a worse cardiovascular (CV) prognosis in this population [6–8].

Patients with ESRD on peritoneal dialysis manifest a high prevalence of mineral metabolism disorders, including elevated concentrations of serum phosphorus, parathyroid hormone (PTH), and decreased calcium. There were a large number of studies focusing on the relationship between mineral metabolism disturbances and mortality risk in dialysis patients [9–12]. Although most studies were carried out in hemodialysis patients, hyperphosphatemia has been proved as a well-established risk factor for all-cause mortality and cardiovascular death[13–17], even in pre-dialysis patients [18] or general population [19–21]. There was also evidence about the significant association between high serum phosphorus with CV event risks (including congestive heart failure, myocardial infarction, transient ischaemic attack or stroke) [22–23]. In addition, the relationship between serum phosphorus and cardiovascular Events has been further confirmed by studies conducted in patients without CKD or CVD [24–25].

LV diastolic dysfunction detected via an increased early diastolic mitral inflow velocity (E) to early mitral annular diastolic velocity (e') ratio (E/e' ratio) has been proved as a marker for increased risk of cardiovascular events and all-cause mortality in CKD patients [26–29]. However, until now, there are no data evaluating the association of serum phosphorus level with LV diastolic dysfunction in peritoneal dialysis patients. Therefore, we initiated this study to explore the relationship of serum phosphorus with left ventricular ultrasound features and function in peritoneal dialysis patients.

Materials and Methods
Study population
Patients with ESRD receiving continuous ambulatory peritoneal dialysis for more than 3 months in a single PD center of the First Affiliated Hospital of Sun Yat-sen University between July 2013 and April 2014 were eligible for inclusion in the study. Additional inclusion criteria were: conventional laboratory measurements including serum phosphorus, and echocardiography were performed. Those who had a history of coronary disease or myocardial infarction, cardiomyopathy, significant arrhythmias, severe mitral valve disease, pericardial disease, or congenital heart disease were excluded. Clinical information, including demographic data, prior medical history (such as hypertension, diabetes, and etiology of CKD) and risk factors for CVD (both traditional and uremia-related risk factors) were collected from medical records.
Baseline clinical assessment, including height, weight, blood pressure, and pulse were also recorded. Body mass index (BMI) was calculated as weight (kg) divided by height square (m)². The study protocol was approved by the ethical review board of the First Affiliated Hospital of Sun Yat-sen University and all patients gave written informed consent. The study was registered with the number NCT02000128.

Laboratory Measurements

All blood samples were drawn from the medial cubital vein in the morning after an overnight fasting of at least 8 h. Biochemical parameters, including serum phosphorus, calcium, intact parathyroid hormone (iPTH), serum albumin, cholesterol, triglyceride, creatinine, pro-brain natriuretic peptide (ProBNP) and hemoglobin (Hb) were measured at the clinical biochemistry laboratory of the First Affiliated Hospital of Sun Yat-sen University. Analytic coefficients of variation were <5%.

Echocardiography

Conventional two-dimensional echocardiography was performed according to guidelines using a commercial ultrasound system (Vivid 7, GE Health Medical, Milwaukee, WI, USA) supported with a multi-frequency transducer (M3S 1.7/3.4 MHz). All echocardiographic measurements were carried out according to American Society of Echocardiography (ASE) criteria [30] by the same independent echocardiologist. Left ventricular mass (LVM) was calculated according to the ASE-recommended cube formula from linear dimensions and indexed to body surface area (LVMI). Left ventricular hypertrophy (LVH) was defined as LVMI >134 g/m² in men and >110g/m² in women [30]. Left ventricular ejection fraction (LVEF) was measured from the parasternal long axis view using Teichholz method [30]. Transmitral inflow was measured in apical four-chamber view using pulsed wave Doppler recordings at the mitral valve leaflet tips. Peak velocities of early filling (E), atrial filling (A), and the E/A ratio were recorded. Early mitral annulus velocity (e’) was measured at the lateral portion of the mitral annulus in an apical four chamber view using a tissue Doppler technique with a Nyquist limit of 15 cm/s. E/e’ ratio was calculated as peak velocities of early filling (E) divided by e’. In our study, LVEF >55% was defined as normal ventricle systolic function. LV filling pressure was considered to be elevated when E/e’ >15 and normal when E/e’ <8. LV diastolic dysfunction was defined when lateral e’ <10 cm/s and E/e’ >15 [31–33].

Statistical analysis

All continuous and normally distributed variables are presented as mean ± standard deviation (SD), while categorical variables were described as proportions. Shapiro-Wilk test was used to assess the normality of variables’ distribution. Homogeneity of variance was checked using Levene’s test. In case of normal distribution and homogeneity of variance, between-group differences were analyzed by ANOVA with LSD post hoc test, while if at least one of the above mentioned criteria was not met, Kruskal–Wallis with Mann–Whitney U post hoc test were used. Pearson and partial Pearson test were used for correlation analysis between serum phosphorus and echocardiographic parameters. Multivariate linear regression models were used to explore the association between serum phosphorus and E/e’ ratio. And multiple logistics regression models were used to analyze the association between serum phosphorus levels and risk of E/e’ ratio >15. Serum phosphorus was considered as both continuous and categorical variables in the multivariate regression analyses. Potential confounders were retained in the final model if they were prior considered important (age, BMI, blood pressure, and medical history of DM and hypertension) or their inclusion resulted in a >10% change in the estimate.
Unadjusted and adjusted regression coefficients or odds ratios (ORs) were reported along with their 95% confidence intervals (CI) and statistical significance was set at P<0.05. All analyses were performed with Statistical Package for Social Sciences (SPSS), Version 13.0 (SPSS Inc., Chicago, IL, USA).

Results

Clinical, Biochemical and Echocardiographic Characteristics by Serum Phosphorus category

We reviewed 240 patients’ medical records resulting in a final sample of 174 PD patients (Fig 1). Out of the 240 patients deemed to be eligible for our study, 60 had either incomplete laboratory or echocardiography data. An additional six patients had either coronary disease, severe mitral valve disease or significant arrhythmias and were excluded from the analysis. We stratified patients into four groups according to the quartiles of serum phosphorus level. Analyses of baseline characteristics of patients were presented in Table 1. The mean age of the 174 patients was 48.5±15.8 year and 48.9% were male. The mean serum phosphorus concentration was 1.7±0.5 mmol/L. Compared with participants with lower concentrations of serum...
phosphorus levels, those with higher concentrations were more likely to have higher BMI. There was a trend of higher levels of serum creatinine (\(P\) for trend < 0.001), iPTH (\(P\) for trend < 0.001), and ProBNP (\(P\) for trend < 0.001) across increasing quartiles of phosphorus, although not all the difference between groups reach statistical significance. However, hemoglobin decreased across increasing phosphorus quartiles (\(P\) < 0.001). All other biochemical characteristics were not significantly different according to phosphorus quartile groups.

Comparisons of echocardiographic characteristics among the four groups were detailed in Table 2. Steady growths of left atrium (LA) diameter, diameters of left ventricular (LV) end diastole and systole as well as increase of LV wall thickness were observed across the increasing quartiles of serum phosphorus in PD patients. In addition, left ventricular muscle mass (LVM) and LVMI were significantly increased in the highest quartile of phosphorus with respect to the lower quartiles (\(P < 0.001\)). Furthermore, LV diastolic function were significantly deteriorated in the highest quartile of phosphorus compared to the lowest quartile (E, 67.8 ± 22.5 vs 95.3 ± 31.3, \(P < 0.001\); E/A ratio, 0.84 ± 0.32 vs 1.11 ± 0.66, \(P = 0.018\); E/ e’ ratio, 9.2 ± 3.7 vs 13.4 ± 6.8, \(P < 0.001\)), while indicator of LV systolic function (ejection fraction) was almost within normal range and quite similar among the four groups (\(P = 0.180\)).

### Table 1. Baseline characteristic of peritoneal dialysis patients by quartiles of serum phosphorus (N = 174).

| Characteristic | Serum phosphorus quartiles (mmol/L) | \(P\) | P-trend |
|---------------|-------------------------------------|-------|--------|
|               | <1.34 (n = 45)                       | 1.34–1.61 (n = 42) | 1.62–1.95 (n = 44) | >1.95 (n = 43) |
| Basic charateristics |                                    |       |        |
| Male          | 25(55.6)                            | 18(42.9) | 21(47.7) | 21(48.8) | 0.703     | 0.639     |
| Age (y)       | 50.4±15.8                           | 47.5±17.8 | 48.9±15.6 | 48.5±15.8 | 0.765     | 0.432     |
| BMI (kg/m²)   | 20.9±3.0                            | 21.8±2.8 | 22.2±3.0 | 23.6±3.1‡§# | 0.001     | <0.001    |
| Dialysis duration (m) |                                    |       |        |
| Prevalent diabetes |                                    |       |        |
| Prevalent hypertension |                                    |       |        |
| Systolic BP (mmHg) |                                    |       |        |
| Diastolic BP (mmHg) |                                    |       |        |
| Laboratory parameter |                                    |       |        |
| Creatinine (umol/L) |                                    |       |        |
| Triglycerides (mmol/L) |                                    |       |        |
| TCHO (mmol/L) | 5.1±1.0                             | 4.7±1.2 | 5.1±1.1 | 5.1±1.3 | 0.282     | 0.523     |
| HDL-C (mmol/L) | 1.1±0.4                             | 1.1±0.3 | 1.2±0.3 | 1.2±0.3 | 0.121     | 0.216     |
| LDL-C (mmol/L) | 2.9±0.8                             | 2.6±0.8 | 2.9±0.9 | 2.9±0.9 | 0.223     | 0.390     |
| Calcium† (mmol/L) | 2.3±0.2                             | 2.4±0.2 | 2.4±0.2 | 2.4±0.2 | 0.255     | 0.527     |
| iPTH (pg/mL) | 300.6(202.2–459.3)                   | 415.8(272.0–619.1)‡ | 459.2(362.6–770.5)‡ | 609.6(482.2–1054.4)‡§# | <0.001 | <0.001 |
| Albumin (g/L) | 37.1±4.1                            | 38.3±2.9 | 37.8±3.5 | 38.6±3.5 | 0.196     | 0.094     |
| Hb (g/L) | 112.9±19.7                          | 113.8±15.3 | 109.4±16.4 | 98.1±20.8‡§# | <0.001 | <0.001 |
| hsCRP (mg/L) | 1.7(0.5–5.4)                        | 0.9(0.3–2.1) | 1.9(0.4–5.1) | 2.4(1.1–4.1) | 0.338     | 0.179     |
| ProBNP (pg/mL) | 2394.0(1126.4–3623.3)               | 2020.0(1059.0–8269.5) | 6956.0(2275.0–15979.0) | 12985.0(2961.0–35000.0)‡§# | <0.001 | <0.001 |

†Corrected for serum albumin concentration (correction formula: albumin-corrected calcium (mmol/L) = total calcium (mmol/L) + 0.02 × (40–albumin g/l)) [34]. BP = blood pressure; iPTH = intact parathyroid hormone; TCHO = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; Hb = hemoglobin; hsCRP = high sensitivity C reactive protein; ProBNP = pro-brain natriuretic peptide.

\(P < 0.05\) compared with quartile 1 (<1.34); 
\(P < 0.05\) compared with quartile 2 (1.34–1.61); 
\(P < 0.05\) compared with quartile 3 (1.62–1.95). 

doi:10.1371/journal.pone.0163659.t001
The Correlation analysis between serum phosphorus and Echocardiographic parameters

In the correlation analysis, serum phosphorus showed a positive association with echocardiographic parameters studied. High serum phosphorus level was significantly correlated with the increase in both left heart dimensions (LA: $r = 0.38, P < 0.001$; LVDd: $r = 0.30, P < 0.001$), wall thicknesses (IVSd: $r = 0.34, P < 0.001$; LVPWd: $r = 0.34, P < 0.001$), and worsening of LV diastolic function (E/ e’ ratio: $r = 0.37, P < 0.001$) (Table 3). Furthermore, positive correlations were also found between serum phosphorus and both of LV mass ($r = 0.44, P < 0.001$) and LVMI ($r = 0.38, P < 0.001$). However, after controlling for traditional and uremia-related CV factors, the correlation between serum phosphorus and these echocardiographic parameters was reduced (Table 3).
risk factors, the positive correlations between serum phosphorus and mentioned echocardiographic parameters disappeared, except for E/e' ratio. After the adjustment, the effect of serum phosphorus on E/e' ratio modestly weakened but still remained statistically significant ($r = 0.26, P = 0.002$).

**Multivariate Linear Regression analysis between serum phosphorus and E/e’ ratio**

In order to further explore the relationship between serum phosphorus level and left ventricular diastolic function, we performed multivariate linear regression analyses of serum phosphorus concentrations with E/e’ ratio. As shown in Table 4, patients with higher phosphorus experienced significantly higher E/e’ ratio ($\beta$: 4.06, 95% CI: 2.53, 5.59). The association was attenuated slightly but remained statistically significant, with the adjustments for demographic data and medical history ($\beta$ for model 1: 3.23, 95% CI: 1.76, 4.70) and other CV risk factors ($\beta$ for model 2: 2.84, 95% CI: 1.30, 4.38). When taken serum phosphorus as category variables with quartiles for further analysis, the association remained only significant at the highest quartile group. The regression coefficient for E/e’ ratio in the highest quartile group was 3.42 (95% CI: 1.45, 5.39) times higher in model 1 and 2.83 (95% CI: 0.77, 4.89) times higher in model 2, compared with the lowest quartile group. Taken together, these results indicated that elevated serum phosphorus levels may be an independent risk factor for LV diastolic dysfunction in patients receiving peritoneal dialysis.

**Multivariate Logistics Regression analysis between serum phosphorus and risk of E/e’ ratio >15**

In present study, we further analyze the relationship between serum phosphorus and left ventricular diastolic dysfunction, defined as E/e’ ratio >15. As shown in Fig 2, patients with phosphorus concentrations between 1.34 and 1.95 mmol/L had approximately twice the prevalence of E/e’ ratio >15, while patients with phosphorus concentrations >1.95 mmol/L had more than fourfold the prevalence, compared to patients with phosphorus concentrations <1.34 mmol/L. Table 5 showed the multiple logistic regression analyses of the relationship between serum phosphorus with E/e’ ratio >15. In unadjusted models, the highest risk for E/e’

| Serum Phosphorus (mmol/L) | Unadjusted | Model 1 [95%CI]* | Model 2 [95%CI]† |
|---------------------------|------------|------------------|------------------|
| <1.34                     | reference  | reference        | reference        |
| 1.34–1.61                 | 1.51[-0.61,3.63] | 1.73[-0.24,3.69] | 1.74[-0.29,3.76] |
| 1.62–1.95                 | 2.30[0.20,4.39] | 2.21[0.27,4.16]  | 2.01[0.02,3.99]  |
| >1.95                     | 4.16[2.05,6.27] | 3.42[1.45,5.39]  | 2.83[0.77,4.89]  |
| P for trend               | <0.001     | 0.001            | 0.008            |
| Continuous                | 4.06[2.53,5.59] | 3.23[1.76,4.70]  | 2.84[1.30,4.38]  |
| P value                   | <0.001     | <0.001           | <0.001           |

*Adjusted for: age, gender, dialysis duration, body mass index, systolic blood pressure, diastolic blood pressure, prevalent diabetes, and prevalent hypertension.
†Adjusted for model 1 covariates plus albumin-corrected calcium, iPTH, serum albumin, TCHO, total triglyceride, HDL-C, LDL-C, hsCRP, serum creatinine and Hb.

CI = confidence interval.

doi:10.1371/journal.pone.0163659.t004
ratio >15 was observed among patients who had serum phosphorus concentrations >1.95 mmol/L (OR: 6.76, 95% CI: 1.78, 25.65). After demographic and medical history adjustments, those in the highest quartile group were 5.60 (95% CI: 1.44, 21.80) times more likely to develop E/e’ ratio >15, relative to those in the lowest quartile of phosphorus. This association was attenuated only slightly with further adjustment for other CV risk factors (OR: 5.24; 95% CI: 1.34, 20.45). When taken serum phosphorus as continuous variable, each 1 mmol/L increase in phosphorus concentrations was associated with approximately fivefold increased risk for E/e’ ratio >15 in the unadjusted model (OR: 4.97; 95% CI: 2.11, 11.69). And the positive associations remained stable even after adjustments for demographic, medical history and other CV risk factors (OR for model 1: 4.56; 95% CI: 1.88, 11.05; OR for model 2: 4.71, 95% CI: 1.90, 11.63).

Discussion

In the present study, we analyzed the relationship of serum phosphorus with indices of LV diastolic function in PD patients. And results showed that high phosphorus was independently associated with the impairment of LV diastolic function, characterized by a progressive rise of E/e’ ratio. Ommen S.R et al. proposed that the E/e’ ratio be used as the initial measurement for
estimation of LV filling pressures that combines the influence of transmitral driving pressure and myocardial relaxation, particularly in those patients with preserved systolic function. Patients with $E'/e' > 15$ can be classified as having elevated filling pressure [32].

Numerous epidemiological studies conducted over the past two decades have demonstrated that hyperphosphatemia was independently associated with increased cardiovascular event rate and CV mortality in patients on dialysis [15,35–37]. However, the serial cardiac changes in dialysis patients with hyperphosphatemia remained unclear. In present study, both the conventional mitral inflow Doppler and the TDI examinations showed an early deterioration of the LV diastolic function in PD patients with the increase of serum phosphorus. In particular, the LV diastolic function worsened with the increase of serum phosphorous concentrations. We found a trend of higher $E'/e'$ ratio ($P$ for trend = 0.008) and increased risk for $E'/e'$ ratio $> 15$ ($P$ for trend = 0.008) across increasing quartiles of phosphorus in PD patients. In further regression analyses, our results showed that highest phosphorus quartile ($> 1.95$ mmol/L) was significantly associated with increased risk of $E'/e'$ ratio $> 15$, irrespective of unadjusted and adjusted models. These findings confirmed a positive association between high serum phosphorus levels and LV diastolic dysfunction, in accordance with those obtained by Galetta et al.[38] in uremic patients on hemodialysis.

Data from Kimura et al. [39] suggested that LV diastolic dysfunction in uremic patients may be attributable to changes of left ventricular mass index. While in present study, it's noteworthy that the positive correlations between serum phosphorus and LVMI disappeared after adjustments, while correlations with $E'/e'$ ratio remained significant. These findings indicate that, though LVH was known as an important risk factor for LVDD, the effects of higher phosphorus levels on worsening LV diastolic function were at least partially independent of LVH. The mechanisms underlying the linkage of serum phosphorus and $E'/e'$ ratio may be multifactors, including endothelial dysfunction, accelerated atherosclerosis, increased arterial stiffness and vascular calcification. Excess phosphorus can promote metastatic calcification of coronary artery and valves, as well as other large vascular of the body [40–47]. This calcification that occurred in the cardiovascular system can decrease the LV relaxation and compliance, which directly lead to LV diastolic dysfunction [48–51]. Moreover, the calcification has been proved to positively correlate with generalized arterial stiffening, arteriosclerosis, higher blood pressure, and decreased coronary perfusion [52–54], all of which in turn may contribute to LV dysfunction.

### Table 5. Odds ratios for the association between quartile of serum phosphorus and $E'/e'$ ratio $> 15$ among peritoneal dialysis patients ($N = 174$).

| Serum Phosphorus (mmol/L) | Odds Ratio       |             |             |             |
|---------------------------|-----------------|-------------|-------------|-------------|
|                           | unadjusted [95% CI] | Model 1 [95% CI]* | Model 2 [95% CI]† |
| <1.34                     | reference       | reference   | reference   |
| 1.34–1.61                 | 2.33 [0.54, 10.00] | 2.14 [0.49, 9.38] | 1.69 [0.37, 7.78] |
| 1.62–1.95                 | 2.65 [0.64, 10.99] | 2.47 [0.58, 10.54] | 2.31 [0.54, 9.86] |
| >1.95                     | 6.76 [1.78, 25.65] | 5.60 [1.44, 21.80] | 5.24 [1.34, 20.45] |
| $P$ for trend             | 0.003           | 0.008       | 0.008       |
| Continuous                | 4.97 [2.11, 11.69] | 4.56 [1.88, 11.05] | 4.71 [1.90, 11.63] |
| $P$ value                 | <0.001          | 0.001       | 0.001       |

*Adjusted for: age, gender, dialysis duration, body mass index, systolic blood pressure, diastolic blood pressure, prevalent diabetes, and prevalent hypertension.
†Adjusted for model 1 covariates plus albumin-corrected calcium, iPTH, serum albumin, TCHO, total triglyceride, HDL-C, LDL-C, hsCRP, serum creatinine and Hb.
CI = confidence interval.

doi:10.1371/journal.pone.0163659.t005
diastolic dysfunction. There were also evidence showing that phosphorus levels were positively associated with subclinical atherosclerosis [55–56] and endothelial dysfunction even in general population [57]. Experimental studies also supported the assumption that phosphorus disorders could acutely increase endothelial dysfunction by impairing vasodilation, leading to large vessel and left ventricular dysfunction [58]. Additionally, animal studies suggested that hyperphosphatemia may increase cardiac fibrosis and aggravate microvascular disease [59], which may also have an adverse impact on LV diastolic function.

To our knowledge, there are no data exploring the relationships between serum phosphorus and echocardiographic features and functions in patients with ESRD receiving peritoneal dialysis. Our study was the first to particularly examine the left ventricular diastolic dysfunction risk associated with serum phosphorus levels in peritoneal dialysis patients. Our results showed that patients with phosphorus concentrations >1.95 mmol/L had more than fourfold the prevalence of E/e' ratio >15, compared to patients with phosphorus concentrations <1.34 mmol/L. And notably, compared with patients in the lowest phosphorus quartile (<1.34 mmol/L) those in the highest phosphorus quartile (>1.95 mmol/L) had a more than fivefold increased odds of E/e' ratio >15 (OR: 5.24 [95%CI 1.34, 20.45]).

However, there are several limitations to the present study. First, we were unable to obtain information on residual kidney function, as well as the use of medications that affect phosphorus metabolism, which have been proved as important determinants of CV mortality in patients on dialysis. Moreover, as higher phosphate levels may also be the result of slower peritoneal transporter status [60], the lack of data on adequacy and peritoneal transporter status may also have impact on analyzing the real relationship of serum phosphorus levels and LVDD. Second, we did not assess the associations between serum phosphorus and severity of LVDD via echocardiography, which may have further correlation with CV prognosis. Finally, we selected Chinese patients undergoing PD with strict exclusion criteria for present study. Thus, our results could not be applied to those patients who have myocardial infarction, cardiomyopathies, arrhythmias, mitral valve disease, pericardial disease, or congenital heart disease, which limited its generalizability.

Conclusions

In conclusion, present study showed that patients with ESRD on peritoneal dialysis have a deterioration of LV diastolic function preceding systolic dysfunction. In particular, we found that higher phosphorus was independently associated with the impairment of LV diastolic function, characterized by a progressive rise in E/e' ratio. Furthermore, our results showed that patients in the highest quartile category of serum phosphorus have 5.24 times higher risk to develop E/e' ratio >15, compared to those in the lowest quartile. All these findings are coincident with the important role of phosphorous disorders on cardiovascular damage. However, it remains unclear whether efforts to reduce serum phosphorus can prevent or improve LV diastolic dysfunction in these patients. Hence, future prospective research should be conducted to determine whether the reduction of serum phosphorus can translate into a lower risk of LV diastolic dysfunction.

Author Contributions

Conceptualization: MY FJY DHL NT.
Formal analysis: MY YQL FJY.
Investigation: YQL WL HL DHL.
Methodology: MY YQL FJY.
Resources: WL HL RF CLL FJY.
Software: NT WL HL RF CLL.
Validation: MY YQL HL RF CLL FJY.
Visualization: FJY DHL.
Writing – original draft: MY YQL.
Writing – review & editing: FJY DHL.

References
1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305. doi: 10.1056/NEJMoa041031 PMID: 15385656
2. Krediet RT, Balafar O. Cardiovascular risk in the peritoneal dialysis patient. NATURE REVIEWS NEPHROLOGY. 2010; 6: 451–460. doi: 10.1038/nrneph.2010.6 PMID: 20567248
3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382: 339–352. doi: 10.1016/S0140-6736(13)60595-4 PMID: 23727170
4. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302: 1782–1789. doi: 10.1001/jama.2009.1488 PMID: 19861670
5. Cai QZ, Lu XZ, Lu Y, Wang AY. Longitudinal changes of cardiac structure and function in CKD (CASCADE study). J Am Soc Nephrol. 2014; 25: 1599–1608. doi: 10.1681/ASN.2013080899 PMID: 24525033
6. Han JH, Han JS, Kim EJ, Doh FM, Koo HM, Kim CH, et al. Diastolic dysfunction is an independent predictor of cardiovascular events in incident dialysis patients with preserved systolic function. PLoS One. 2015; 10: e118694. doi: 10.1371/journal.pone.0118694 PMID: 25739020
7. Zaslavsky LM, Pinotti AF, Gross JL. Diastolic dysfunction and mortality in diabetic patients on hemodialysis: a 4.25-year controlled prospective study. J Diabetes Complications. 2005; 19: 194–200. doi: 10.1016/j.jdiacomp.2004.12.001 PMID: 15993932
8. Barberato SH, Bucharels S, Sousa AM, Costantini CO, Costantini C, Pecoits R. Prevalence and Prognostic Impact of Diastolic Dysfunction in Patients with Chronic Kidney Disease on Hemodialysis. ARQUIVO BRASILEIROS DE CARDIOLOGIA. 2010; 94: 457–462 PMID: 20339814
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208–2218. doi: 10.1097/01.ASN.0000133041.27682.A2 PMID: 15284307
10. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelsohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44: 34–38 PMID: 15486872
11. Abe M, Okada K, Soma M. Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients. 2013; 5: 1002–1023. doi: 10.3390/nu5031002 PMID: 23525083
12. Covic A, Kohlwala P, Bernal M, Robbins S, Chalain A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2008; 24: 1506–1523. doi: 10.1093/ndt/gfn613 PMID: 19001560
13. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16: 520–528. doi: 10.1681/ASN.2004070602 PMID: 15615819
14. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 2251–2257. doi: 10.2215/CJN.00810110 PMID: 20688884
15. Palmer SC, Hayen A, Macaskill P, Pelegirini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with
chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011; 305: 1119–1127. doi: 10.1001/jama.2011.308 PMID: 21406649

16. Da J, Xie X, Wolf M, Distinguish S, Wang J, Zha Y, et al. Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. Am J Kidney Dis. 2015; 66: 258–265. doi: 10.1053/ajkd.2015.01.009 PMID: 25804679

17. Rivara MB, Ravel V, Kalantar-Zadeh K, Strefa E, Lau WL, Nissenson AR, et al. Uncorrected and Albuin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Dialysis Management. J Am Soc Nephrol. 2015; 26: 1671–1681. doi: 10.1681/ASN.2014050472 PMID: 25613037

18. Rozentzyt P, Niedziela J, Nowak J, Iwinski J, Szygula-Jurkiewicz B, Kawecka E, et al. [Plasma phosphorus as cardiovascular risk factor in persons with preserved kidney function]. Kardiol Pol. 2012; 70: 938–942 PMID: 22993006

19. Foley RN. Phosphate Levels and Cardiovascular Disease in the General Population. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2009; 4: 1136–1139. doi: 10.2215/CJN.1784–1792. doi: 10.1161/CIRCULATION AHA.10 9.851873 PMID: 19841303

20. Tonelli M, Curnan G, Pfeffer M, Thadani R, Melamed ML, et al. Relation between alkaline fosfate and cardiovascular disease in patients with end-stage renal disease: data from the North American Renal Data System. J Am Soc Nephrol. 2016; 27: 4407–4416. doi: 10.1681/ASN.2015080856 PMID: 27345995

21. Dominguez JR, Kestenbaum B, Chonchol M, Block G, Laughlin GA, Lewis CE, et al. Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study. Am J Kidney Dis. 2013; 61: 555–563. doi: 10.1053/j.ajkd.2012.11. 033 PMID: 23261120

22. Lutsey PL, Alonso A, Michos ED, Loehr LR, Astor BC, Coresh J, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. 2014; 100: 756–764. doi: 10.3945/ajc n.114.085167 PMID: 25030784

23. Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, et al. Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. PLoS One. 2014; 9: e114678. doi: 10.1371/journal. pone.0114678 PMID: 25494334

24. McGovern AP, de Lusignan S, van Vlymen J, Liyanage H, Tomson CR, Gallagher H, et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013; 8: e74996. doi: 10.1371/journal.pone. 0074996 PMID: 24040373

25. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino RS, Gaziano JM, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167: 879–885. doi: 10.1001/archinte.167.9.879 PMID: 17502528

26. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, et al. Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr. 2006; 19: 266–273. doi: 10.1016/j..echo.2005.10.006 PMID: 16500488

27. Iwabuchi Y, Ogawa T, Inoue T, Otsuka K, Nitta K. Elevated E/E’ predicts cardiovascular events in hemodialysis patients with preserved systolic function. Intern Med. 2012; 51: 155–160 PMID: 22246482

28. Kim JK, Kim SG, Kim MG, Kim SE, Kim SJ, Kim HJ, et al. Left ventricular diastolic dysfunction as a predictor of rapid decline of residual renal function in patients with peritoneal dialysis. J Am Soc Echocardiogr. 2012; 25: 411–420. doi: 10.1016/j.echo.2011.11.026 PMID: 22198883

29. Kim MK, Kim B, Lee JY, Kim JS, Han BG, Choi SO, et al. Tissue Doppler-derived E/e’ ratio as a parameter for assessing diastolic heart failure and as a predictor of mortality in patients with chronic kidney disease. Korean J Intern Med. 2013; 28: 35–44. doi: 10.3904/kijm.2013.28.1.35 PMID: 23345995

30. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1–39. doi: 10.1016/j.echo.2014.10.003 PMID: 25558473

31. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998; 32: 865–875 PMID: 9768704

32. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative prospective study. Circulation. 2000; 102: 1788–1794 PMID: 11023953

33. Naghesh SF, Appleton CP, Gilbertho TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. J Am Soc Echocardiogr. 2009; 22: 107–133. doi: 10.1016/j.echo.2008.11.023 PMID: 19187853
Serum Phosphorus Is Associated with Left Ventricular Diastolic Dysfunction

Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4: 643–646 PMID: 4758544

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607–617 PMID: 9531176

Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO₄(4), Ca x PO₄(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131–2138 PMID: 11562412

Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl. 2003; S111–S114. doi: 10.1046/j.1523-1755.63.s85.26.x PMID: 12753279

Galetta F, Cupisti A, Franzoni F, Femia FR, Rossi M, Barsotti G, et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med. 2005; 258: 378–384. doi: 10.1111/j.1365-2796.2005.01544.x PMID: 16164578

Kimura H, Takeda K, Tsuruya K, Mukai H, Muto Y, Okuda H, et al. Left ventricular mass index is an independent determinant of diastolic dysfunction in patients on chronic hemodialysis: a tissue Doppler imaging study. Nephron Clin Pract. 2011; 117: c67–c73. doi: 10.1159/000319649 PMID: 20689327

Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006; 21: 1915–1920. doi: 10.1093/ndt/gfl118 PMID: 16554319

Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial. 2007; 20: 139–143. doi: 10.1111/j.1525-139X.2007.00261.x PMID: 17374088

Shang D, Xie Q, Ge X, Yan H, Tian J, Kuang D, et al. Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients. BMC Nephrol. 2015; 16: 107. doi: 10.1186/s12882-015-0103-8 PMID: 26187601

Linefsky JP, O’Brien KD, Katz R, de Boer IH, Barasch E, Jenny NS, et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol. 2011; 58: 291–297. doi: 10.1016/j.jacc.2010.11.073 PMID: 21737022

Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis. 2011; 58: 826–834. doi: 10.1053/j.ajkd.2011.07.020 PMID: 21956015

Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109: 697–711. doi: 10.1161/CIRCRESAHA.110.234914 PMID: 21885837

Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009; 20: 381–387. doi: 10.1681/ASN.2008040349 PMID: 19073826

Tuttle KR, Short RA. Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. Clin J Am Soc Nephrol. 2009; 4: 1968–1973. doi: 10.2215/CJN.01250209 PMID: 19965546

Yoon HE, Chung S, Whang HC, Shin YR, Hwang HS, Chung HW, et al. Abdominal aortic calcification is associated with diastolic dysfunction, mortality, and nonfatal cardiovascular events in maintenance hemodialysis patients. J Korean Med Sci. 2012; 27: 870–875. doi: 10.3346/jkms.2012.27.8.870 PMID: 22876052

An WS, Lee SM, Park TH, Kim SE, Kim KH, Park YJ, et al. Association between diastolic dysfunction by color tissue Doppler imaging and vascular calcification on plain radiographs in dialysis patients. Kidney Blood Press Res. 2012; 35: 619–626. doi: 10.1159/000339646 PMID: 22948793

Honma H, Ohno T, Tokita Y, Matsuura T, Fujimoto H, Yoshinaga A, et al. Aortic valve calcification and increased stiffness of the proximal thoracic ascending aorta: association with left ventricular diastolic dysfunction and early chronic kidney disease. J Med Ultrason (2001). 2011; 38: 179. doi: 10.1007/s10396-011-0318-7 PMID: 22785582

Fujiu A, Ogawa T, Matsuda N, Ando Y, Nitta K. Aortic arch calcification and arterial stiffness are independent factors for diastolic left ventricular dysfunction in chronic hemodialysis patients. Circ J. 2008; 72: 1768–1772 PMID: 18802313

Aoki A, Kojima F, Uchida K, Tanaka Y, Nitta K. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients. Geriatr Gerontol Int. 2009; 9: 246–252. doi: 10.1111/j.1447-0594.2009.00528.x PMID: 19702934

Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant. 2008; 23: 586–593. doi: 10.1093/ndt/gfm660 PMID: 17933842
54. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 1241–1248. doi: 10.2215/CJN.02190507 PMID: 17928470

55. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, Wilson PW, et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis. 2008; 199: 424–431. doi: 10.1016/j.atherosclerosis.2007.11.004 PMID: 18093595

56. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009; 20: 397–404. doi: 10.1681/ASN.2008020141 PMID: 18987306

57. Di Marco GS, Konig M, Stock C, Wiesinger A, Hillebrand U, Reiermann S, et al. High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int. 2013; 83: 213–222. doi: 10.1038/ki.2012.300 PMID: 22913982

58. Watari E, Taketani Y, Kitamura T, Tanaka T, Ohminami H, Abuduli M, et al. Fluctuating plasma phosphorus level by changes in dietary phosphorus intake induces endothelial dysfunction. J Clin Biochem Nutr. 2015; 56: 35–42. doi: 10.3164/jcbn.14-96 PMID: 25678749

59. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003; 63: 1296–1301. doi: 10.1046/j.1523-1755.2003.00864.x PMID: 12631346

60. Courivaud C, Davenport A. Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Preservation. Perit Dial Int. 2016; 36: 85–93. doi: 10.3747/pdi.2014.00173 PMID: 26224788